Why It Matters
A federal court’s decision to strike down 2023 abortion drug restrictions marks a significant legal setback for efforts to limit mifepristone access and injects fresh uncertainty into the federal regulatory landscape surrounding the medication. The ruling throws into question how the Trump administration will handle the drug’s approval as competing lawsuits work through the courts and the FDA conducts its own safety review.
What Happened
U.S. District Court Judge Robert Ballou ruled Thursday that the Food and Drug Administration failed to adequately justify its 2023 restrictions on mifepristone, the most common medication used for abortion. The Virginia-based judge found the agency’s regulatory modifications unlawful and ordered them sent back to the FDA for reconsideration.
The decision stems from a 2023 lawsuit filed by abortion providers in Kansas, Montana, and Virginia who challenged the restrictions as excessive and lacking scientific foundation. Those restrictions, imposed by the Biden administration, required prescribing pharmacies and clinicians to obtain special certification and mandated that prescribers and patients sign risk acknowledgment forms.
Judge Ballou stated that “the 2023 REMS modification is unlawful and must be remanded to the FDA for review,” though he did not establish a timeline for the agency to complete its analysis.
Notably, the 2023 rules had actually loosened prior restrictions by allowing mifepristone to be dispensed without an in-person provider visit for the first time, expanding access to residents of 13 states with near-total abortion bans through mail delivery.
By the Numbers
2023 — Year the restrictions were imposed and the lawsuit was filed
10 weeks — Gestational age limit for mifepristone use under the rules
13 states — Number of states with near-total abortion bans where expanded access became available
6 months — Expected duration of the FDA’s broader safety review, according to Trump administration officials
September — Month when oral arguments are scheduled in the Louisiana appeals court case challenging telehealth prescription provisions
Zoom Out
Ballou’s ruling aligns with a similar decision reached in October by a federal judge in Hawaii, who found the 2023 restrictions arbitrary. The two decisions reflect broader judicial skepticism of the restrictions across different circuits.
Meanwhile, the FDA has indicated it is conducting a comprehensive safety review of mifepristone and asked courts to hold off deciding mifepristone cases until that review concludes. According to statements made to the Wall Street Journal in June, Trump administration officials estimated the review would take approximately six months and conclude after the midterm elections.
The legal landscape remains fragmented. Three additional lawsuits filed by attorneys general in states with abortion bans are challenging the expanded access that the 2023 rules created. A case before the Fifth U.S. Circuit Court of Appeals involving Louisiana seeks to eliminate the telehealth prescription provision, with oral arguments set for September. The Fifth Circuit initially granted an emergency request to block telehealth access, but the U.S. Supreme Court reversed that order. Cases brought by Missouri (joined by Idaho and Kansas) seek to reinstate 2016-level restrictions, while Texas and Florida are pursuing a case aimed at revoking the drug’s approval entirely.
What’s Next
The FDA must now determine how to respond to Ballou’s remand order. The agency’s broader safety review, expected to conclude within six months, will likely shape its next regulatory move. Meanwhile, competing state lawsuits continue advancing through federal appellate courts, setting up potential conflicts between judicial rulings and regulatory action. The Supreme Court could ultimately weigh in if the circuits split on key questions about the drug’s approval or the scope of FDA authority over its distribution.